Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancerMyrto Moutafi, David L. Rimm, Charles T. Robbins et al.|Laboratory Investigation|2022Cited by 141
Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancerMyrto Moutafi, Ioannis Vathiotis|Journal for ImmunoTherapy of Cancer|2021Cited by 51
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial ProfilingMyrto Moutafi, David L. Rimm, Sandra Martínez-Morilla et al.|Journal of Thoracic Oncology|2022Cited by 40
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancerThazin Nwe Aung, David L. Rimm, James Monkman et al.|Nature Genetics|2025Cited by 33
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithmsThazin Nwe Aung, David L. Rimm, Saba Shafi et al.|EBioMedicine|2022Cited by 33